| __timestamp | Bristol-Myers Squibb Company | Incyte Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 165772000 |
| Thursday, January 1, 2015 | 5001000000 | 196614000 |
| Friday, January 1, 2016 | 5002000000 | 303251000 |
| Sunday, January 1, 2017 | 4849000000 | 366406000 |
| Monday, January 1, 2018 | 4551000000 | 434407000 |
| Tuesday, January 1, 2019 | 4871000000 | 468711000 |
| Wednesday, January 1, 2020 | 7661000000 | 516922000 |
| Friday, January 1, 2021 | 7690000000 | 739560000 |
| Saturday, January 1, 2022 | 7814000000 | 1002140000 |
| Sunday, January 1, 2023 | 7772000000 | 1161300000 |
| Monday, January 1, 2024 | 8414000000 | 1242157000 |
Infusing magic into the data realm
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Bristol-Myers Squibb Company and Incyte Corporation, two giants in the industry, have shown contrasting strategies over the past decade. From 2014 to 2023, Bristol-Myers Squibb's SG&A expenses have surged by approximately 36%, peaking in 2022. In contrast, Incyte Corporation's expenses have grown by a staggering 600% during the same period, reflecting its aggressive expansion strategy.
While Bristol-Myers Squibb maintains a steady increase, Incyte's rapid growth in SG&A costs suggests a focus on scaling operations. This divergence highlights the strategic choices companies make in balancing cost management with growth ambitions. As the pharmaceutical landscape evolves, these insights offer a glimpse into how industry leaders navigate financial challenges.
Cost Management Insights: SG&A Expenses for Pfizer Inc. and Incyte Corporation
Who Optimizes SG&A Costs Better? Sanofi or Bristol-Myers Squibb Company
Sanofi and Incyte Corporation: SG&A Spending Patterns Compared
Bristol-Myers Squibb Company or GSK plc: Who Manages SG&A Costs Better?
Bristol-Myers Squibb Company vs Summit Therapeutics Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Bristol-Myers Squibb Company vs MannKind Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Geron Corporation
SG&A Efficiency Analysis: Comparing Bristol-Myers Squibb Company and Celldex Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Zoetis Inc. and Incyte Corporation
Incyte Corporation and MorphoSys AG: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Incyte Corporation and Geron Corporation